Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma

被引:1
|
作者
Cao, Yenong [1 ]
Afzal, Muhammad Zubair [2 ]
Shirai, Keisuke [2 ]
机构
[1] Dartmouth Hitchcock Med Ctr, Dept Internal Med, Lebanon, NH 03766 USA
[2] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA
关键词
skin cancer; unwanted effects; adverse reactions;
D O I
10.1136/bcr-2021-243713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mucosal melanoma is a rare subtype of melanoma and represents a unique diagnosis and treatment challenge. Immune-checkpoint inhibitors (ICIs) have revolutionised metastatic melanoma treatment, and one of the leading regimens is the combination of ipilimumab (anti-cytotoxic T lymphocyte-associated antigen 4: CTLA4) and nivolumab (anti-programmed cell death protein 1: PD1). We report a case of a patient with metastatic mucosal melanoma treated with ipilimumab and nivolumab who developed multiple immune-related adverse events (irAEs) including uveitis, type I diabetes complicated by diabetic ketoacidosis, destructive thyroiditis, hepatitis and vitiligo. Endocrinopathies including type 1 diabetes and hypothyroidism were treated with insulin and levothyroxine. Hepatitis was responsive to steroids. She had sustained complete response 12 months after discontinuation of the combination therapy. With the wide usage of ICIs in multiple types of malignancies, it is important for general practioners to recognise common and serious irAEs due to ICIs.
引用
收藏
页数:3
相关论文
共 50 条
  • [42] ASSOCIATION OF IMMUNE-RELATED ADVERSE EVENTS WITH PROGNOSIS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH NIVOLUMAB
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Homma, Chie
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    JOURNAL OF UROLOGY, 2019, 201 (04): : E71 - E71
  • [43] Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
    Almutairi, Abdulaali R.
    McBride, Ali
    Slack, Marion
    Erstad, Brian L.
    Abraham, Ivo
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [44] Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
    Fink, Morten
    Vittrup, Anders Schwartz
    Bastholt, Lars
    Svane, Inge Marie
    Donia, Marco
    Luczak, Adam A.
    Ruhlmann, Christina H.
    Guldbrandt, Louise Mahncke
    Koehler, Ulrich Heide
    Winther, Mette Lerche
    Ellebaek, Eva
    Haslund, Charlotte Aaquist
    Schmidt, Henrik
    CANCERS, 2021, 13 (21)
  • [45] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Toshiyuki Sumi
    Motoki Sekikawa
    Yuta Nagahisa
    Keigo Matsuura
    Naoki Shijubou
    Koki Kamada
    Hiroki Watanabe
    Yuichi Yamada
    Yusuke Tanaka
    Hirofumi Chiba
    Investigational New Drugs, 2022, 40 : 1315 - 1321
  • [46] Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer
    Sumi, Toshiyuki
    Sekikawa, Motoki
    Nagahisa, Yuta
    Matsuura, Keigo
    Shijubou, Naoki
    Kamada, Koki
    Watanabe, Hiroki
    Yamada, Yuichi
    Tanaka, Yusuke
    Chiba, Hirofumi
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1315 - 1321
  • [47] Nivolumab-induced Pancreatitis: An Immune-related Adverse Event
    Saito, Hiroaki
    Ono, Kana
    RADIOLOGY, 2019, 293 (03) : 521 - 521
  • [48] Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
    Yamauchi, Ichiro
    Yasoda, Akihiro
    Matsumoto, Shigemi
    Sakamori, Yuichi
    Kim, Young Hak
    Nomura, Motoo
    Otsuka, Atsushi
    Yamasaki, Toshinari
    Saito, Ryoichi
    Kitamura, Morimasa
    Kitawaki, Toshio
    Hishizawa, Masakatsu
    Kawaguchi-Sakita, Nobuko
    Fujii, Toshihito
    Taura, Daisuke
    Sone, Masakatsu
    Inagaki, Nobuya
    PLOS ONE, 2019, 14 (05):
  • [49] Association between genetic variants and the risk of nivolumab-induced immune-related adverse events
    Udagawa, Chihiro
    Nakano, Mari Hara
    Yoshida, Teruhiko
    Ohe, Yuichiro
    Kato, Ken
    Mushiroda, Taisei
    Zembutsu, Hitoshi
    PHARMACOGENOMICS, 2022, 23 (16) : 887 - 901
  • [50] Impact of sex on immune-related adverse events in patients with melanoma
    Ottaviano, Margaret
    Mallardo, Domenico
    Vitale, Maria Grazia
    Vanella, Vito
    Fordellone, Mario
    Festino, Lucia
    Trojaniello, Claudia
    Sparano, Francesca
    Facchini, Bianca Arianna
    Cioli, Eleonora
    Isaja, Antonio
    Cavalcanti, Ernesta
    Capone, Mariaelena
    Madonna, Gabriele
    Paone, Miriam
    Chiodini, Paolo
    Caraco, Corrado
    Simeone, Ester
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)